The Daily Toke

March 28, 2026

# THC & Politics: Military Opens Doors While States Chase Revenue

The U.S. Army just made a historic pivot on cannabis records. Effective April 20—yes, really—recruits with a single marijuana possession or paraphernalia conviction can now enlist without a waiver. It's a direct response to recruitment pressure, and it signals something bigger: the federal government's decades-old stance on cannabis is fracturing along practical lines. When the military needs bodies more than it needs to enforce stigma, the stigma loses. Meanwhile, Congress has 16 cannabis bills in play for 2025-2026, with the MORE Act leading the pack at 62 sponsors. Federal legalization still looks unlikely this cycle, but the legislative machinery is turning.

💰 MONEY MOVES States are lining up revenue projections like lottery tickets. Pennsylvania Gov. Josh Shapiro is betting $729 million in new annual tax revenue on legalization—but his own legislature can't agree on how to structure it. Republican Sen. Dan Laughlin wants a new Cannabis Control Board; Democratic Rep. Dan Frankel prefers the existing Liquor Control Board. Last year, Frankel's legalization bill died in Laughlin's committee. Nothing has changed except the urgency: Pennsylvania faces a $5 billion budget shortfall. Legalization is one fix among many, but it's stuck on process. Idaho activists, meanwhile, just cleared the signature threshold for a medical marijuana ballot measure. A commissioned economic analysis projects $108.5 million in annual retail sales by year six, generating $6.5 to $28 million in state revenue depending on tax structure. That's real money in a conservative state—and Idaho hasn't had a legal marijuana market since prohibition. 💰 MONEY MOVES U.S. legal marijuana sales rebounded to $30.5 billion in 2026 after the first-ever decline in 2025 ($29.1 billion). The industry is maturing. New York and Ohio's expanded retail access kept the national market afloat last year, but pricing compression and supply saturation are the new normal. By 2030, legal marijuana sales are projected to hit $43.3 billion—steady growth, but nothing like the explosive 2020s expansion.

State-level chaos is becoming the pattern. Ohio passed Senate Bill 56 in December, and it took effect March 20. The law bans THC beverages, restricts hemp-derived cannabis products, eliminates legal protections for marijuana consumers, and lets people lose unemployment benefits, organ transplants, and parenting rights based solely on cannabis use. Activists collected volunteer signatures to block it via referendum but fell short of 250,000. A lawsuit from Ohio breweries is pending at the state Supreme Court—they're arguing Gov. Mike DeWine overstepped his authority when he vetoed a provision allowing bars to sell THC drinks through 2026.

Meanwhile, Massachusetts is wrestling with a ballot question designed to repeal 2016's legalization. The Coalition for a Healthy Massachusetts claims legalization made the state "less comfortable to live in" because of marijuana odors and potency concerns—but their own question would allow any adult to gift up to an ounce to anyone else, potentially reviving the black market they claim to oppose. House lawmakers spotted the logical trap immediately. Massachusetts also advanced bills to create psilocybin therapy pilot programs, joining Hawaii, Utah, and New Mexico in exploring psychedelics for mental health. 🚀 THIS IS COOL The FDA has already designated psilocybin and MDMA as breakthrough therapies for depression, PTSD, and end-of-life anxiety—meaning states are moving ahead of federal rescheduling to build infrastructure for therapies that could reshape mental health treatment. Delaware just approved medical cannabis in hospitals for terminally ill patients. Georgia is expanding medical access to include vaping and new conditions. Mississippi passed three medical marijuana bills, removing potency caps on oils and eliminating mandatory follow-up doctor visits.

🤔 THINK ABOUT IT The Army is lowering barriers to recruitment by accepting cannabis convictions. Ohio is stripping legal protections from cannabis consumers. Pennsylvania needs $729 million and can't decide who regulates it. Congress has 16 legalization bills with no clear path. And the market keeps growing—$43.3 billion projected by 2030. What does it tell you when the institution charged with national security sees cannabis prohibition as a recruitment obstacle, while individual states race to collect revenue from something still federally illegal? The federal-state gap isn't closing. It's widening, and everyone's racing to decide whether to lead or follow.

March 28, 2026

Texas' hemp industry is bracing for a massive shakeout as new state regulations take effect March 31, capping total THC content at 0.3% and imposing dramatic licensing fee increases that could force widespread closures across roughly 1,500 retail locations. The Texas Department of State Health Services rules represent a fundamental shift from the previous Delta-9 THC standard to a "Total THC" measurement that combines Delta-9 and THCA—a compound that converts to intoxicating THC when heated. This redefinition would effectively ban popular smokable products including pre-rolled joints and hemp flower that are currently legal under existing law. 💰 MONEY MOVES The financial hit is immediate and severe: manufacturer licenses jump from $258 to $10,000 annually, while retail registrations skyrocket from $155 to $5,000, threatening to eliminate the $8 billion sector that has rapidly expanded since hemp legalization in 2019.

The regulatory overhaul has triggered legal pushback. On March 17, hemp retailer Boomtown Vapor LLC filed a lawsuit in Travis County arguing that the Texas Department of State Health Services is overstepping its authority by unilaterally redefining what qualifies as legal hemp. The plaintiff is seeking a temporary restraining order, warning that without court intervention, thousands of small businesses face immediate closure and widespread layoffs. The lawsuit also challenges the $5,000 registration fee as a "prohibitive tax" designed to destroy the industry rather than regulate it fairly. A judge has yet to rule on the request as the March 31 deadline approaches.

The Texas situation reflects a broader national pattern. A federal spending bill provision would ban most hemp-derived THC products nationwide beginning November 12, 2026, setting a threshold of just 0.4 milligrams of THC per container—effectively eliminating the entire intoxicating hemp market unless Congress acts. Diana Eberlein, chair of the Coalition for Adult Beverage Alternatives, described the impending federal deadline as an "existential threat" to the industry. However, legislative efforts are underway to delay or regulate rather than prohibit: Rep. James Baird introduced H.R. 7010 to push the effective date to November 2028, while a bipartisan bill from Rep. Morgan Griffith (R-Virginia) and Rep. Marc Veasey (D-Texas) would authorize the FDA to regulate hemp-derived THC products instead of banning them outright. Eberlein noted that these proposals signal growing "interest in regulation versus prohibition."

Meanwhile, other states are moving independently. Ohio's hemp restrictions took effect March 24, clearing shelves at gas stations and convenience stores, while Pennsylvania district attorneys are actively lobbying state lawmakers to regulate intoxicating hemp products sold in smoke shops. 🤔 THINK ABOUT IT These products carry zero recorded overdose deaths in human history—yet regulators are moving faster to restrict them than they have to address alcohol, which kills approximately 95,000 Americans annually, or prescription opioids, which kill over 16,000 per year.

For retailers, edibles and beverages may offer a potential lifeline under Texas' new regime, but shops built around higher-margin smokable products face a brutal pivot. Some operators have warned that the fee increases combined with product restrictions could push sales into illicit markets, creating the opposite of the public safety outcome regulators claim to seek. The Texas Hemp Business Council and individual retailers are urging lawmakers to reconsider, noting that the regulatory path chosen—prohibition wrapped in compliance costs—differs sharply from the FDA oversight model emerging in federal legislation.

The March 31 deadline will reshape one of Texas' fastest-growing retail sectors overnight. Whether courts intervene, whether Congress delays the federal ban, and whether states ultimately choose regulation or prohibition will determine whether the hemp industry survives this wave of restrictions or whether billions in legal commerce simply shift underground.

March 28, 2026

# THC in Science: Mental Health Claims Collapse, Medicare Coverage Launches, and Research Gaps Widen

A sweeping meta-analysis published in The Lancet has dealt a significant blow to widespread claims about cannabis's effectiveness for treating mental health disorders. The study, led by Dr. Jack Wilson from the University of Sydney's Matilda Centre and encompassing 54 clinical trials spanning 1980 to 2025, found little to no evidence that medicinal cannabis helps with anxiety, depression, or PTSD. The findings directly contradict the beliefs of a substantial portion of Americans who report using cannabis specifically to manage mood and anxiety disorders. What's particularly striking is that researchers identified potential harms—including a greater likelihood of developing psychosis and delayed access to more effective treatments—making this not merely a case of ineffectiveness, but one where cannabis use may actively backfire for people seeking mental health relief.

The research arrives at a critical moment: approximately one in five U.S. adults now uses CBD, yet the FDA has approved exactly one CBD product for any condition. 🚀 THIS IS COOL That lone approved medication—Epidiolex—has established itself as the gold standard for epilepsy treatment, with long-term data showing sustained seizure reduction through 144 weeks and evidence extending to rare off-label epilepsy syndromes. The gap between what the market is selling and what science can actually verify remains enormous. A 2024 meta-analysis found a significant anxiolytic signal for CBD, but it was built on just eight studies involving 316 total participants—hardly a foundation for confident recommendations. For pain, one of the most common reasons people purchase CBD, a 2026 Cochrane Review of 21 studies and 2,187 participants found no clear evidence that CBD-dominant products achieve meaningful neuropathic pain relief. Meanwhile, a German study of nearly 1,000 older adults did show that full-spectrum CBD-dominant extracts outperformed synthetic THC for chronic pain, suggesting that the composition and formulation of cannabis products matter far more than simple cannabinoid ratios.

The so-called "entourage effect"—the theory that cannabis compounds work better together than in isolation—remains a productive scientific hypothesis with partial clinical support, not the settled fact that many retailers and marketers claim. Sativex, a near-1:1 THC:CBD pharmaceutical spray, does show evidence of synergy in cancer pain management, and epilepsy research hints at whole-plant advantages. But well-designed studies have also produced contradictory findings, and the relationship between CBD and THC is far more complex than popular descriptions suggest. Some research even shows the opposite of what conventional wisdom predicts: high-dose CBD can actually amplify THC's effects through liver enzyme interactions. 🚀 THIS IS COOL One genuine breakthrough came from formulation science: a new study found that powder-based CBD formulations retain over 90% of their potency under standard conditions, compared to roughly 20% retention in oil-based products exposed to light. This kind of attention to manufacturing details could significantly extend shelf life and improve product consistency across the market.

Meanwhile, federal policy is moving faster than the evidence base can keep up. The Centers for Medicare & Medicaid Services announced details for a pilot program launching April 1, 2026, that will allow participating healthcare organizations to furnish up to $500 annually in hemp-derived CBD to eligible Medicare beneficiaries at no cost to patients. 💰 MONEY MOVES The program is narrower than initial announcements suggested: products must be orally administered, contain no more than 0.3% delta-9 THC, and come with third-party testing. However, the initiative has sparked controversy—critics argue CMS may be circumventing FDA drug approval standards by covering products outside the traditional pharmaceutical pathway. The political origins of this program are worth noting: it emerged from lobbying by Commonwealth Project founder Howard Kessler, a Trump ally who leveraged personal ties to the president to advance cannabis reform. Simultaneously, a hemp-derived THC products ban is scheduled to take effect in November 2026, creating regulatory chaos. Daniel Kruger, a cannabis policy expert at the University at Buffalo, argues that an outright ban is unnecessary and counterproductive—better to regulate all intoxicating cannabis products consistently, mandate testing, and require transparency rather than creating black markets. Industry estimates peg the CBD wellness market at $8.5 billion to $13 billion in 2026 alone, making regulation a question of when, not whether.

Scientific curiosity is also expanding into less-studied territory. Hebrew University researchers recently found that CBD and CBG compounds improved liver function in mouse models of non-alcoholic fatty liver disease (NAFLD), a condition affecting nearly 24% of U.S. adults. The mechanism appears to involve enhanced energy production and lysosomal function in liver cells, with cannabis compounds acting like a metabolic "backup battery" during dietary stress. These are early-stage findings—mice, not humans—but they hint at therapeutic applications far beyond the mental health claims that just collapsed. Meanwhile, states continue experimenting with regulatory models: Colorado's marijuana enforcement division reported a 99% success rate in underage sales compliance checks, while Georgia lawmakers passed a bill expanding medical cannabis access by allowing vaping and adding new qualifying conditions.

🤔 THINK ABOUT IT The emerging picture of cannabis science is nuanced and honest: some applications—particularly epilepsy—have world-class clinical evidence. Others, like mental health treatment, have collapsed under scrutiny. Still others remain genuinely uncertain but worth studying. The real scandal isn't that cannabis doesn't work for everything—no medicine does. It's that widespread marketing claims have raced ahead of actual evidence, and that federal policy keeps lurching between extremes instead of settling on consistent, science-based regulation. The same political class that bans a zero-overdose-death product continues to permit alcohol, which kills roughly 95,000 Americans annually, and prescription opioids, which kill over 16,000 per year. The data speaks for itself.

March 28, 2026

Texas smokable hemp products will disappear from store shelves on March 31, as the Texas Department of State Health Services enforces new regulations capping total THC in smokable goods at 0.3%—essentially banning hemp flower, pre-rolls, and similar items that customers have legally purchased for years. Monday, March 30, marks the final day retailers can sell these products, reshaping a market where smokable hemp has dominated sales. At Gruene Botanicals in New Braunfels, owner Sean Timmerman estimates smokable products represent about 80% of his store's revenue. Across El Paso and Southeast Texas, smoke shop managers report hemp-related sales account for 20 to 30 percent of their business—a significant hit they're bracing for as the rules take effect.

The new regulations do more than ban smokables. The Texas Department of State Health Services is also imposing higher licensing fees, stricter testing and labeling requirements, child-resistant packaging mandates, and raising the purchase age to 21. 💰 MONEY MOVES Many smaller retailers who built their businesses around legal hemp products now face a dramatic inventory shift—and potential legal exposure. Attorney Brock Benjamin warned that the reclassification effectively treats smokable hemp like marijuana under Texas law, where possession of less than four ounces is a Class B misdemeanor and anything above that is Class A. Benjamin predicted law enforcement will likely take a broad approach, seizing products retailers believed were legal under the old rules. The sudden change puts businesses in legal jeopardy for selling products that were compliant just days earlier.

Edible hemp products like gummies and THC-infused beverages remain legal under the new rules, since they're regulated by the Texas Alcoholic Beverage Commission, which hasn't issued new restrictions. Timmerman said his store will pivot toward these compliant products—including nonalcoholic THC-infused daiquiris that have been popular during river season—though he acknowledges many customers remain unaware the ban is happening. 🚀 THIS IS COOL Some retailers see opportunity in this reset. Timmerman told customers, "They may take the icing off the top, but the cake is still there," suggesting edibles could partially fill the gap left by smokables. He's expressed optimism that dismantling the unregulated hemp market could pave the way for Texas to eventually develop an actual medical or recreational cannabis program, following models already established in other states.

The timing raises questions about priorities.

🤔 THINK ABOUT IT The federal government kills zero Americans annually from cannabis overdose—a perfect safety record spanning recorded history. Alcohol kills roughly 95,000 Americans per year. Prescription opioids kill over 16,000 annually. Texas is tightening restrictions on a zero-death substance while those products remain legal and heavily marketed. What does that calculation tell you about how drug policy actually gets made?

The legal landscape remains in flux. Customers who purchased smokable hemp products before March 31 can legally possess and use them—the ban only applies to sales. But small retailers and consumers facing this sudden market reset don't have that luxury of time. The question now is whether Texas follows through on the study phase Patrick mentioned, or whether this is simply a first step toward tighter restrictions on THC products overall.